Stifel Nicolaus Increases Artivion (NYSE:AORT) Price Target to $30.00

Artivion (NYSE:AORT) had its price objective boosted by Stifel Nicolaus from $28.00 to $30.00 in a report released on Friday, Benzinga reports. The firm currently has a buy rating on the stock.

Other research analysts also recently issued reports about the company. Needham & Company LLC restated a buy rating and issued a $30.00 price target on shares of Artivion in a research note on Friday, August 9th. Lake Street Capital upped their price objective on Artivion from $28.00 to $30.00 and gave the company a buy rating in a research note on Tuesday, July 2nd. Finally, Oppenheimer lifted their target price on Artivion from $25.00 to $30.00 and gave the stock an outperform rating in a research note on Friday, August 9th.

Artivion Stock Up 0.6 %

NYSE:AORT opened at $25.39 on Friday. The company has a current ratio of 5.63, a quick ratio of 4.04 and a debt-to-equity ratio of 1.07. The stock has a 50-day moving average price of $26.14 and a two-hundred day moving average price of $23.54. Artivion has a 1 year low of $12.16 and a 1 year high of $29.24. The stock has a market cap of $1.06 billion, a price-to-earnings ratio of -105.79 and a beta of 1.74.

Artivion (NYSE:AORT) last issued its quarterly earnings results on Thursday, August 8th. The company reported $0.07 EPS for the quarter, beating analysts’ consensus estimates of $0.03 by $0.04. The company had revenue of $98.02 million for the quarter, compared to analyst estimates of $97.70 million. Artivion had a positive return on equity of 3.81% and a negative net margin of 2.22%. As a group, equities analysts expect that Artivion will post 0.2 earnings per share for the current year.

Insider Buying and Selling

In other Artivion news, Director Anthony B. Semedo sold 9,709 shares of the company’s stock in a transaction on Tuesday, August 13th. The stock was sold at an average price of $24.99, for a total value of $242,627.91. Following the transaction, the director now directly owns 34,159 shares of the company’s stock, valued at approximately $853,633.41. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In other Artivion news, SVP Jean F. Holloway sold 2,383 shares of Artivion stock in a transaction on Thursday, August 15th. The stock was sold at an average price of $25.76, for a total value of $61,386.08. Following the completion of the transaction, the senior vice president now directly owns 165,099 shares of the company’s stock, valued at approximately $4,252,950.24. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Anthony B. Semedo sold 9,709 shares of the stock in a transaction on Tuesday, August 13th. The stock was sold at an average price of $24.99, for a total value of $242,627.91. Following the sale, the director now directly owns 34,159 shares in the company, valued at $853,633.41. The disclosure for this sale can be found here. In the last 90 days, insiders sold 24,679 shares of company stock valued at $626,518. Company insiders own 8.10% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. First Eagle Investment Management LLC increased its holdings in Artivion by 8.1% in the 1st quarter. First Eagle Investment Management LLC now owns 570,242 shares of the company’s stock valued at $12,066,000 after buying an additional 42,705 shares during the period. Wasatch Advisors LP grew its holdings in shares of Artivion by 108.8% during the 1st quarter. Wasatch Advisors LP now owns 1,083,568 shares of the company’s stock valued at $22,928,000 after purchasing an additional 564,549 shares during the last quarter. Vanguard Group Inc. increased its holdings in shares of Artivion by 1.3% during the first quarter. Vanguard Group Inc. now owns 2,664,855 shares of the company’s stock worth $56,388,000 after buying an additional 33,982 shares in the last quarter. Tidal Investments LLC bought a new position in Artivion in the first quarter valued at about $257,000. Finally, Allspring Global Investments Holdings LLC boosted its stake in shares of Artivion by 291.3% during the first quarter. Allspring Global Investments Holdings LLC now owns 5,580 shares of the company’s stock valued at $118,000 after purchasing an additional 4,154 shares in the last quarter. Institutional investors and hedge funds own 86.37% of the company’s stock.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.